Research on Implementation of Interventions in Tuberculosis Control in Low- and Middle-Income Countries: A Systematic Review

English version České info

Background:
Several interventions for tuberculosis (TB) control have been recommended by the World Health Organization (WHO) over the past decade. These include isoniazid preventive therapy (IPT) for HIV-infected individuals and household contacts of infectious TB patients, diagnostic algorithms for rule-in or rule-out of smear-negative pulmonary TB, and programmatic treatment for multidrug-resistant TB. There is no systematically collected data on the type of evidence that is publicly available to guide the scale-up of these interventions in low- and middle-income countries. We investigated the availability of published evidence on their effectiveness, delivery, and cost-effectiveness that policy makers need for scaling-up these interventions at country level.

Methods and Findings:
PubMed, Web of Science, EMBASE, and several regional databases were searched for studies published from 1 January 1990 through 31 March 2012 that assessed health outcomes, delivery aspects, or cost-effectiveness for any of these interventions in low- or middle-income countries. Selected studies were evaluated for their objective(s), design, geographical and institutional setting, and generalizability. Studies reporting health outcomes were categorized as primarily addressing efficacy or effectiveness of the intervention. These criteria were used to draw landscapes of published research. We identified 59 studies on IPT in HIV infection, 14 on IPT in household contacts, 44 on rule-in diagnosis, 19 on rule-out diagnosis, and 72 on second-line treatment. Comparative effectiveness studies were relatively few (n = 9) and limited to South America and sub-Saharan Africa for IPT in HIV-infection, absent for IPT in household contacts, and rare for second-line treatment (n = 3). Evaluations of diagnostic and screening algorithms were more frequent (n = 19) but geographically clustered and mainly of non-comparative design. Fifty-four studies evaluated ways of delivering these interventions, and nine addressed their cost-effectiveness.

Conclusions:
There are substantial gaps in published evidence for scale-up for five WHO-recommended TB interventions settings at country level, which for many countries possibly precludes program-wide implementation of these interventions. There is a strong need for rigorous operational research studies to be carried out in programmatic settings to inform on best use of existing and new interventions in TB control.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Research on Implementation of Interventions in Tuberculosis Control in Low- and Middle-Income Countries: A Systematic Review. PLoS Med 9(12): e32767. doi:10.1371/journal.pmed.1001358
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001358

Souhrn

Zdroje

1. (2010) Global tuberculosis control: a short update to the 2009 report. Geneva: World Health Organization.

2. Stop TB Partnership, World Health Organization (2010) The Global Plan to Stop TB, 2011–2015. Geneva: World Health Organization.

3. LienhardtC, CobelensFGJ (2011) Operational research for improved tuberculosis control: the scope, the needs and the way forward. Int J Tuberc Lung Dis 15: 6–13.

4. SchünemannHJ, SchünemannAHJ, OxmanAD, BrozekJ, GlasziouP, et al. (2008) Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336: 1106–1110.

5. Last JM (2000) A dictionary of epidemiology. 4th edition. New York: Oxford University Press.

6. SandersD, HainesA (2006) Implementation research is needed to achieve international health goals. PLoS Med 3: e186 doi:10.1371/journal.pmed.0030186.

7. ThiamS, LeFevreAM, HaneF, NdiayeA, BaF, et al. (2007) Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA 297: 380–386.

8. PaiM, MinionJ, SteingartK, RamsayA (2010) New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr Opin Pulm Med 16: 271–284.

9. MannG, SquireSB, BissellK, EliseevP, Du ToitE, et al. (2010) Beyond accuracy: creating a comprehensive evidence base for TB diagnostic tools. Int J Tuberc Lung Dis 14: 1518–1524.

10. VassallA, CompernolleP (2006) Estimating the resource needs of scaling-up HIV/AIDS and tuberculosis interventions in sub-Saharan Africa: a systematic review for national policy makers and planners. Health Policy 79: 1–15.

11. Tuberculosis (z.d.). Available: http://www.stoptb.org/global/plan/main/default.asp. Accessed 2 Nov 2010.

12. OnozakiI, RaviglioneM (2010) Stopping tuberculosis in the 21st century: goals and strategies. Respirology 15: 32–43.

13. Stop TB Partnership: TB/HIV working group (2003) Guidelines for implementing collaborative TB and HIV programme activities. Geneva: World Health Organization.

14. World Health Organization (2006) Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva: World Health Organization.

15. WHO (2003) Treatment of tuberculosis: guidelines for national programmes. 3rd edition. Geneva: World Health Organization.

16. WHO (2007) Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. Geneva: World Health Organization.

17. WHO (2000) Guidelines for establishing DOTS-PLUS pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). Geneva: World Health Organization.

18. DurovniB, CavalcanteSC, SaraceniV, VellozoV, IsraelG, et al. (2010) The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study. AIDS 24 Suppl 5: S49–56.

19. GrantAD, CoetzeeL, FieldingKL, LewisJJ, NtsheleS, et al. (2010) “Team up against TB”: promoting involvement in Thibela TB, a trial of community-wide tuberculosis preventive therapy. AIDS 24 Suppl 5: S37–44.

20. Mello FC deQ, Bastos LG doV, SoaresSLM, RezendeVMC, CondeMB, et al. (2006) Predicting smear negative pulmonary tuberculosis with classification trees and logistic regression: a cross-sectional study. BMC Public Health 6: 43.

21. LambertML, SugulleH, SeyoumD, AbdurahmanS, AbdinasirA, et al. (2003) How can detection of infectious tuberculosis be improved? Experience in the Somali region of Ethiopia. Int J Tuberc Lung Dis 7: 485–488.

22. World Health Organization (2007) Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents Recommendations for HIV-prevalent and resource-constrained settings. Geneva: World Health Organization.

23. HoltzTH, KaberaG, MthiyaneT, ZingoniT, NadesanS, et al. (2011) Use of a WHO-recommended algorithm to reduce mortality in seriously ill patients with HIV infection and smear-negative pulmonary tuberculosis in South Africa: an observational cohort study. Lancet Infect Dis 11: 533–540.

24. WalleyJ, KunutsorS, EvansM, ThoulassJ, KatabiraE, et al. (2011) Validation in Uganda of the new WHO diagnostic algorithm for smear-negative pulmonary tuberculosis in HIV prevalent settings. J Acquir Immune Defic Syndr 57: e93–100.

25. SotoA, SolariL, GotuzzoE, AcinelliR, VargasD, et al. (2011) Performance of an algorithm based on WHO recommendations for the diagnosis of smear-negative pulmonary tuberculosis in patients without HIV infection. Trop Med Int Health 16: 424–430.

26. KooleO, ThaiS, KhunKE, PeR, van GriensvenJ, et al. (2011) Evaluation of the 2007 WHO guideline to improve the diagnosis of tuberculosis in ambulatory HIV-positive adults. PLoS ONE 6: e18502 doi:10.1371/journal.pone.0018502.

27. WilsonD, MbheleL, BadriM, MorroniC, NachegaJ, et al. (2011) Evaluation of the World Health Organization algorithm for the diagnosis of HIV-associated sputum smear-negative tuberculosis. Int J Tuberc Lung Dis 15: 919–924.

28. NguyenDTM, HungNQ, GiangLT, DungNH, LanNTN, et al. (2011) Improving the diagnosis of pulmonary tuberculosis in HIV-infected individuals in Ho Chi Minh City, Viet Nam. Int J Tuberc Lung Dis 15: 1528–1534.

29. Van DeunA, MaugAKJ, SalimMAH, DasPK, SarkerMR, et al. (2010) Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182: 684–692.

30. LovedayM, WallengrenK, VoceA, MargotB, ReddyT, et al. (2012) Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 16: 209–215.

31. LeimaneV, DravnieceG, RiekstinaV, StureI, KammererS, et al. (2010) Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000–2004. Eur. Respir J 36: 584–593.

32. PodewilsLJ, HoltzT, RiekstinaV, SkripconokaV, ZarovskaE, et al. (2011) Impact of malnutrition on clinical presentation, clinical course, and mortality in MDR-TB patients. Epidemiol Infect 139: 113–120.

33. ClarkPM, KaragozT, Apikoglu-RabusS, IzzettinFV (2007) Effect of pharmacist-led patient education on adherence to tuberculosis treatment. Am J Health Syst Pharm 64: 497–505.

34. KunawararakP, PongpanichS, ChantawongS, PokaewP, TraisathitP, et al. (2011) Tuberculosis treatment with mobile-phone medication reminders in northern Thailand. Southeast Asian J Trop Med Public Health 42: 1444–1451.

35. QuelapioMID, MiraNRC, Orillaza-ChiRB, BelenV, MuñezN, et al. (2010) Responding to the multidrug-resistant tuberculosis crisis: mainstreaming programmatic management to the Philippine National Tuberculosis Programme. Int J Tuberc Lung Dis 14: 751–757.

36. HellerT, LessellsRJ, WallrauchCG, BärnighausenT, CookeGS, et al. (2010) Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 14: 420–426.

37. AchaJ, SweetlandA, GuerraD, ChalcoK, CastilloH, et al. (2007) Psychosocial support groups for patients with multidrug-resistant tuberculosis: five years of experience. Glob Public Health 2: 404–417.

38. BonnetM, PardiniM, MeacciF, OrrùG, YesilkayaH, et al. (2011) Treatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection. PLoS ONE 6: e23081 doi:10.1371/journal.pone.0023081.

39. Smith PG, Morrow RH (1991) Methods for field trials of interventions against tropical diseases: a toolbox. New York: Oxford University Press.

40. Murray DM (1998) Design and analysis of group-randomized trials. 1st edition. New York: Oxford University Press.

41. The Gambia Hepatitis Study Group (1987) The Gambia Hepatitis Intervention Study. Cancer Res 47: 5782–5787.

42. HusseyMA, HughesJP (2007) Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials 28: 182–191.

43. BrownCA, LilfordRJ (2006) The stepped wedge trial design: a systematic review. BMC Med Res Methodol 6: 54.

44. SquireSB, RamsayARC, van den HofS, MillingtonKA, LangleyI, et al. (2011) Making innovations accessible to the poor through implementation research. Int J Tuberc Lung Dis 15: 862–870.

45. NathansonE, GuptaR, HuamaniP, LeimaneV, PasechnikovAD, et al. (2004) Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J. Tuberc Lung Dis 8: 1382–1384.

46. NathansonE, Lambregts-van WeezenbeekC, RichML, GuptaR, BayonaJ, et al. (2006) Multidrug-resistant tuberculosis management in resource-limited settings. Emerging Infect Dis 12: 1389–1397.

47. DwanK, AltmanDG, ArnaizJA, BloomJ, ChanA-W, et al. (2008) Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE 3: e3081 doi:10.1371/journal.pone.0003081.

48. GetahunH, GranichR, SculierD, GunnebergC, BlancL, et al. (2010) Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS 24 Suppl 5: S57–65.

49. LeungCC, RiederHL, LangeC, YewWW (2011) Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur Respir J 37: 690–711.

50. GetahunH, HarringtonM, O'BrienR, NunnP (2007) Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 369: 2042–2049.

51. CobelensFGJ, HeldalE, KimerlingME, MitnickCD, PodewilsLJ, et al. (2008) Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med 5: e150 doi:10.1371/journal.pmed.0050150.

52. MountFW, FerebeeSH (1961) Preventive effects of isoniazid in the treatment of primary tuberculosis in children. N Engl J Med 265: 713–721.

53. FerebeeSH, MountFW (1962) Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am. Rev Respir Dis 85: 490–510.

54. EgsmoseT, Ang'awaJO, PotiSJ (1965) The use of isoniazid among household contacts of open cases of pulmonary tuberculosis. Bull World Health Organ 33: 419–433.

55. Del CastilloH, BautistaL, JacintoC, LorenzoC, LapuzS, et al. (1965) Chemoprophylaxis in the Philippines. A controlled pilot study among household contacts of tuberculosis cases. Bull Quezon Institute 7: 277–290.

56. ComstockGW, FerebeeSH, HammesLM (1967) A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 95: 935–943.

57. KochiA (1997) Tuberculosis control–is DOTS the health breakthrough of the 1990s? World Health Forum 18: 225–232.

58. Stop TB Partnership (2011) An international roadmap for tuberculosis research. Geneva: World Health Organization. Available: www.stoptb.org/assets/.

59. Stop TB Partnership, The Global Fund to Fight AIDS, Tuberculosis and Malaria (2011) Priorities in operational research to improve tuberculosis care and control. Geneva: World Health Organization.

60. MaraisBJ, RaviglioneMC, DonaldPR, HarriesAD, KritskiAL, et al. (2010) Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet 375: 2179–2191.

61. World Health Organization (2011) Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries: policy statement.WHO/HTM/TB/2011.18. Available: http://www.who.int/tb/publications/2011/en/index.html. Geneva: World Health Organization.

62. WHO (2006) WHO Report 2006. Tuberculosis control: surveillance, planning, financing. Geneva: World Health Organization.

63. (2008) Anti-tuberculosis drug resistance in the world. Fourth global report. Geneva: World Health Organization.

64. ThorpeKE, ZwarensteinM, OxmanAD, TreweekS, FurbergCD, et al. (2009) A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 62: 464–475.

65. CainKP, McCarthyKD, HeiligCM, MonkongdeeP, TasaneeyapanT, et al. (2010) An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 362: 707–716.

66. MonkongdeeP, McCarthyKD, CainKP, TasaneeyapanT, NguyenHD, et al. (2009) Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am J Respir Crit Care Med 180: 903–908.